[1] 1POUNDER R E, NG D. The prevalence of Helicobacter pylori infection in different countries[J]. Aliment Pharmacol Ther, 1995, 9(Suppl 2): 33-39.
[2] 2REN S, CAI P P, LIU Y Q, et al. Prevalence of Helicobacter pylori infection in China: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2022, 37(3): 464-470. doi:  10.1111/jgh.15751
[3] 3刘文忠, 谢勇, 陆红, 等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学, 2017, 22(6): 346-360.
[4] 中华医学会消化病学分会幽门螺杆菌学组. 2022中国幽门螺杆菌感染治疗指南[J]. 胃肠病学, 2022, 27(3): 150-162.
[5] PILOTTO A, FRANCESCHI M. Helicobacter pylori infection in older people[J]. World J Gastroenterol, 2014, 20(21): 6364-6373. doi:  10.3748/wjg.v20.i21.6364
[6] 6俞菊英, 尹强龙, 陈勇, 等. 嘉兴市秀洲区体检和门诊人群幽门螺杆菌感染状况调查[J]. 胃肠病学, 2018, 23(6): 363-365.
[7] 7孟欣颖, 赵东明, 周长宏, 等. 青岛市幽门螺杆菌现症感染率的调查分析[J]. 中国临床保健杂志, 2015, 18(5): 517-518. doi:  10.3969/J.issn.1672-6790.2015.05.022
[8] 8YAMAJI Y, HIRATA Y. Treatment for Helicobacter pylori appears to reduce the incidence of gastric cancer: eradication effect or screening effect?[J]. Gut, 2020, 69(3): 605-606. doi:  10.1136/gutjnl-2018-318206
[9] SARRI G L, GRIGG S E, YEOMANS N D. Helicobacter pylori and low-dose aspirin ulcer risk: a meta-analysis[J]. J Gastroenterol Hepatol, 2019, 34(3): 517-525. doi:  10.1111/jgh.14539
[10] SALLES N, MÉGRAUD F. Current management of Helicobacter pylori infections in the elderly[J]. Expert Rev Anti Infect Ther, 2007, 5(5): 845-856. doi:  10.1586/14787210.5.5.845
[11] PEA F. Antimicrobial treatment of bacterial infections in frail elderly patients: the difficult balance between efficacy, safety and tolerability[J]. Curr Opin Pharmacol, 2015, 24: 18-22. doi:  10.1016/j.coph.2015.06.006
[12] GILLIES M, RANAKUSUMA A, HOFFMANN T, et al. Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication[J]. CMAJ, 2015, 187(1): E21-E31. doi:  10.1503/cmaj.140848
[13] DAVIDSON R J. In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections[J]. Infect Drug Resist, 2019, 12: 585-596. doi:  10.2147/IDR.S187226
[14] MILBERG P, ECKARDT L, BRUNS H J, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes[J]. J Pharmacol Exp Ther, 2002, 303(1): 218-225. doi:  10.1124/jpet.102.037911
[15] SCHEMBRI S, WILLIAMSON P A, SHORT P M, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies[J]. BMJ, 2013, 346: f1235. doi:  10.1136/bmj.f1235
[16] Svanström H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study[J]. BMJ. 2014 Aug 19;349: g4930.
[17] VOELKER R. Another caution for clarithromycin[J]. JAMA, 2018, 319(13): 1314.
[18] WINKEL P, HILDEN J, HANSEN J F, et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial[J]. Int J Cardiol, 2015, 182: 459-465. doi:  10.1016/j.ijcard.2015.01.020
[19] GANDHI S, FLEET J L, BAILEY D G, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury[J]. JAMA, 2013, 310(23): 2544-2553. doi:  10.1001/jama.2013.282426
[20] FIGUEIRA-COELHO J, PEREIRA O, PICADO B, et al. Acute hepatitis associated with the use of levofloxacin[J]. Clin Ther, 2010, 32(10): 1733-1737. doi:  10.1016/j.clinthera.2010.09.004
[21] KANG J, WANG L, CHEN X L, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG[J]. Mol Pharmacol, 2001, 59(1): 122-126.
[22] GORELIK E, MASARWA R, PERLMAN A, et al. Fluoroquinolones and cardiovascular risk: a systematic review, Meta-analysis and network Meta-analysis[J]. Drug Saf, 2019, 42(4): 529-538. doi:  10.1007/s40264-018-0751-2
[23] SINGH S, NAUTIYAL A. Aortic dissection and aortic aneurysms associated with fluoroquinolones: a systematic review and meta-analysis[J]. Am J Med, 2017, 130(12): 1449-1457. doi:  10.1016/j.amjmed.2017.06.029
[24] ETMINAN M, SODHI M, GANJIZADEH-ZAVAREH S, et al. Oral fluoroquinolones and risk of mitral and aortic regurgitation[J]. J Am Coll Cardiol, 2019, 74(11): 1444-1450. doi:  10.1016/j.jacc.2019.07.035
[25] VAN DER LINDEN P D, STURKENBOOM M C, HERINGS R M, et al. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids[J]. Arch Intern Med, 2003, 163(15): 1801-1807. doi:  10.1001/archinte.163.15.1801
[26] BAIK S, LAU J, HUSER V, et al. Association between tendon ruptures and use of fluoroquinolone, and other oral antibiotics: a 10-year retrospective study of 1 million US senior Medicare beneficiaries[J]. BMJ Open, 2020, 10(12): e034844. doi:  10.1136/bmjopen-2019-034844
[27] CHOU H W, WANG J L, CHANG C H, et al. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin inTaiwan[J]. Clin Infect Dis, 2013, 57(7): 971-980. doi:  10.1093/cid/cit439
[28] HEATON P C, FENWICK S R, BREWER D E. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study[J]. J Clin Pharm Ther, 2007, 32(5): 483-487. doi:  10.1111/j.1365-2710.2007.00853.x
[29] ALTıN C, KANYıLMAZ S, BAYSAL S, et al. QT interval prolongation due to metronidazole administration[J]. Anadolu Kardiyol Derg, 2011, 11(5): 468-469.
[30] COHEN O, SAAR N, SWARTZON M, et al. First report of metronidazole-induced QT interval prolongation[J]. Int J Antimicrob Agents, 2008, 31(2): 180-181. doi:  10.1016/j.ijantimicag.2007.10.006
[31] CINA S J, RUSSELL R A, CONRADI S E. Sudden death due to metronidazole/ethanol interaction[J]. Am J Forensic Med Pathol, 1996, 17(4): 343-346. doi:  10.1097/00000433-199612000-00013
[32] WILLIAMS C S, WOODCOCK K R. Do ethanol and metronidazole interact to produce a disulfiram-like reaction?[J]. Ann Pharmacother, 2000, 34(2): 255-257. doi:  10.1345/aph.19118
[33] BLYDEN G T, SCAVONE J M, GREENBLATT D J. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam[J]. J Clin Pharmacol, 1988, 28(3): 240-245. doi:  10.1002/j.1552-4604.1988.tb03139.x
[34] O’REILLY R A. The stereoselective interaction of warfarin and metronidazole in man[J]. N Engl J Med, 1976, 295(7): 354-357. doi:  10.1056/NEJM197608122950702
[35] ERADIRI O, JAMALI F, THOMSON A B. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn’s disease[J]. Biopharm Drug Dispos, 1988, 9(2): 219-227. doi:  10.1002/bod.2510090210
[36] MEAD P B, GIBSON M, SCHENTAG J J, et al. Possible alteration of metronidazole metabolism by phenobarbital[J]. N Engl J Med, 1982, 306(24): 1490.
[37] LOFT S, DØSSING M, SONNE J, et al. Lack of effect of cimetidine on the pharmacokinetics and metabolism of a single oral dose of metronidazole[J]. Eur J Clin Pharmacol, 1988, 35(1): 65-68. doi:  10.1007/BF00555509
[38] RAJNARAYANA K, REDDY M S, VIDYASAGAR J, et al. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole[J]. Arzneimittelforschung, 2004, 54(2): 109-113.